Our Founders
Founded by Dr. Leslie J. Berg and Dr. Joonsoo Kang, ImmVue was born from a breakthrough insight in T cell biology. While studying how autoreactive T cells moved through lung tissue, they observed that the cells abruptly stopped when ITK was blocked. That discovery led to a bold question: if inhibiting ITK could halt immune cells, could activating it help drive cancer-fighting T cells into tumors? That idea became the foundation for ImmVue’s ITK agonist platform.
Our Team
Our Company
Audacious. Resolute. Transformative.
This Is The A.R.T. Of ImmVue.
These aren’t just words on a wall. They’re the values we live by—every meeting, every milestone, every decision.
At ImmVue Therapeutics, we are fostering a culture where Audacious ideas thrive, Resolute collaboration drives progress, and Transformative solutions emerge. We believe in empowering each team member to contribute their unique strengths, supporting one another in pursuit of groundbreaking advancements in science to provide the next generation of therapies for patients.
Together, we create an environment where innovation, trust, and shared purpose pave the way for success.
Our scientific advisory board
Arlene Sharpe, MD, PhD
Matthew Krummel, PhD
Andrea Schietinger, PhD
Barry Sleckman, MD, PhD
Andrea Reboldi, PhD
Arlene Sharpe, MD, PhD
Matthew Krummel, PhD
Andrea Schietinger, PhD
Barry Sleckman, MD, PhD
Andrea Reboldi, PhD
Our Partners
ImmVue collaborates with a network of academic, clinical, and industry partners that provide expertise in structural biology, computational drug discovery, translational immunology, and clinical oncology. Together, these collaborations accelerate the translation of the IMPAKT platform into clinical therapies
Contact
We’re actively engaging collaborators, investors, and talent passionate about shaping the future of immune therapeutics
info@immvue.com
Partner with Us